1871 Folsom Street
About Clovis OncologyClovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado.
April 20, 2009
Founders: Patrick Mahaffy, and Erle Mast
CEO and Co-founder: Patrick Mahaffy
CMO (Medical): Lindsey Rolfe
Please click here for Clovis Oncology job opportunities.
Please click here for clinical trial information.
254 articles with Clovis Oncology
Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1
Clovis Oncology, Inc. will announce its second quarter 2019 financial results on Thursday, August 1, 2019, before the open of the U.S. financial markets.
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the appointment of Ginger L. Graham as Board Chair to Clovis’ Board of Directors, following the retirement of former Board Chair Dr. M. James Barrett.
Expanded Rubraca® (Rucaparib) Data from Clovis Oncology’s ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting
Clovis Oncology, Inc. announced multiple datasets being presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, May 31 – June 4, 2019.
Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca®▼ in Advanced Ovarian Cancer
Quality-adjusted progression free survival (QA-PFS) and quality-adjusted time without cancer related symptoms or toxicity (Q-TWiST) demonstrate the benefit of Rubraca maintenance treatment over placebo from a patient perspective
Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and the designs of other ongoing rucaparib trials
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2019, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for the rest of the year.
Clovis Oncology, Inc. announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2019 on Tuesday, May 14, 2019 at 2:20 PM Pacific Time.
Clovis Oncology Enters into Non-Dilutive Clinical Trial Financing with TPG Sixth Street Partners for up to $175 Million
Financing to fund quarterly expenses related to the ATHENA first-line maintenance clinical trial in ovarian cancer, beginning in Q2 2019 through study completion
Clovis Oncology to Announce First Quarter 2019 Financial Results and Host Webcast Conference Call on May 7
Clovis Oncology, Inc. will announce its first quarter 2019 financial results on Tuesday, May 7, 2019, before the open of the U.S. financial markets.
Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019
Clovis is evaluating a potential clinical and regulatory path forward for Rubraca in pancreatic cancer
Maintenance Therapy With Rucaparib Shows Clinical Responses in a Subgroup of Patients With Pancreatic Cancer
Maintenance treatment with the PARP inhibitor rucaparib was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2- mutated pancreatic cancer sensitive to platinum-based chemotherapy, according to results from an interim analysis of an ongoing phase II clinical trial presented at the AACR Annual Meeting 2019, March 29–April 3.
The American Association for Cancer Research (AACR) Annual Meeting is taking place in Atlanta. Here’s a look at just a few stories coming out of the meeting.
Investigating new testing options to identify patients for clinical trials.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six abstracts highlighting progress in the Rubraca clinical development and lucitanib preclinical research programs will be presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting taking place March 29 – April 3 in Atlanta.
Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress
Maintenance treatment with Rubraca significantly improved PFS and reduced the risk of progression vs placebo regardless of whether tumors had deleterious germline BRCA mutations
Clovis Oncology, Inc. announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 at 11:15 a.m. Eastern time.
Clovis Oncology Announces Availability of Rubraca®▼ (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany
Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with platinum-sensitive relapsed ovarian cancer, regardless of BRCA status
2018 Rubraca® (rucaparib) U.S. sales totaled $95.4M, including $30.4M for the fourth quarter of 2018
Clovis Oncology, Inc. announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern time.
Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
Combinations of ALKS 4230 with Rucaparib and Lucitanib to be Evaluated in Multiple Preclinical Tumor Models